Cannabidiol
Brand Names: Epidiolex
Methodology & AI Transparency ⓘ
Cannabidiol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage epidiolex: is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.
- 2 Real-world patient consensus: Zero-PHI community consensus: 77% favorable across 14 logged regimens (Epidiolex).
- 3 Typical cash cost range: Dispensing cost comparison spans $79.38 mail/discount cash up to $194.48 uninsured retail (federal NADAC $1.7500).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Cannabidiol include diarrhea (8.4%), fatigue (8.8%), somnolence (6.1%).
Ask our AI Specialists anything about Cannabidiol
Cannabidiol Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage epidiolex: is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older. EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients 1 year of age and older ( 1 )
12.1 Mechanism of Action The precise mechanisms by which EPIDIOLEX exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.
Systemic exposure to Cannabidiol reflects Approximately 62% to 74% enteral uptake across labeled Cannabidiol strengths absorption kinetics and phase i cyp3a4, cyp2c19, cyp1a2 hepatic clearance and subsequent renal metabolite filtration, sustaining receptor engagement across a Steady-state plasma equilibrium reached over 6–17 hour t½ intervals for Cannabidiol half-life window (peak plasma tmax within 2.5 to 5 hours (cannabidiol) response profile).
Dosing protocols (100 mg/mL Solution or Prescriber-supervised Cannabidiol escalation or taper window) balance efficacy (77.00% patient satisfaction across 14 logs) against fatigue (8.8% of reports), diarrhea (8.4% of reports), somnolence (6.1% of reports), with strict avoidance in 4 contraindications epidiolex is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product .; hypersensitivity to cannabidiol or any of the ingredients in epidiolex ( 4 ).
Monitor serum digoxin concentrations when initiating or adjusting Cannabidiol due to transporter overlap.
Co-prescribing strong CYP3A4 inhibitors or inducers can modify Cannabidiol metabolic elimination kinetics.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- 4 CONTRAINDICATIONS EPIDIOLEX is contraindicated in patients with a history of hypersensitivity to cannabidiol or any of the ingredients in the product .
- Hypersensitivity to cannabidiol or any of the ingredients in EPIDIOLEX ( 4 )
Logged Side-Effect Incidence (14 Reports)
Cannabidiol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cannabidiol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Effect of Nabiximols on Driving Ability in Adults with Chronic Tic Disorders: Conclusion: Treatment with nabiximols does not impair skills relevant to driving in those patients with tic disorders who were fit to drive at baseline and even improved fitness to. Cannabis and cannabinoid research • 2024-10-15 • Phase III Randomized Trial | N = 64 | 88/100 | PMID 38265476 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy, safety, and how the body absorbs the medicine of nanodispersible Nanodispersible CBD was therapeutically safe with no serious side effects, well tolerated, and effective for the treatment of mild to moderate anxiety, as well as associated depression and sleep quality disturbances. Asian journal of psychiatry • 2024-07-15 • Phase III Randomized Trial | N = 89 | 88/100 | PMID 38797087 ↗ |
| Managing Dravet syndrome: Can Placebo response Make a Real Difference? (What New Research Reveals) Placebo had little impact on convulsive seizure-free days and Caregiver Global Impression of Change versus baseline, suggesting that these metrics may help differentiate placebo and active treatment effects in future studies. Epilepsy & behavior : E&B • 2024-07-15 • Phase III Randomized Trial | N = 35 | 88/100 | PMID 38677101 ↗ |
| Can This Approach Help? Inside the Latest Research on Dravet syndrome seizure frequency and clustering: Placebo-treated patients in Post-hoc analyses suggested that potential relationships could exist between BMI, age and convulsive seizure cluster variation. Epilepsy & behavior : E&B • 2024-06-15 • Phase III Randomized Trial | N = 35 | 88/100 | PMID 38643658 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Results: CBD showed no difference in relationship to placebo for primary and secondary outcomes. Cannabis and cannabinoid research • 2023-04-15 • Phase III Randomized Trial | N = 18 | 88/100 | PMID 35749710 ↗ |
Cannabidiol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.7500/unit (~$52.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $194.48 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $79.38 / mo | View logs ↓ |
Cannabidiol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Cannabidiol RxNorm Concept ID | 2058900 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.7500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $194.48 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $79.38 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Cannabidiol Patient Community, Cohort Filters & Dosage Logs
Deterministic Cannabidiol reference combining NIH RxNorm (2058900), Medicaid NADAC ($1.7500/unit), and anonymous cohort outcomes (77% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Cannabidiol community threads and patient logs by age, biological sex, dosage, and treatment duration.